Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer

Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer

Copyright © 2016. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 176(2017) vom: 01. März, Seite 63-70
1. Verfasser: Zirakzadeh, A Ali (VerfasserIn)
Weitere Verfasser: Kinn, Johan, Krantz, David, Rosenblatt, Robert, Winerdal, Malin E, Hu, Jin, Hartana, Ciputra Adijaya, Lundgren, Christian, Bergman, Emma Ahlén, Johansson, Markus, Holmström, Benny, Hansson, Johan, Sidikii, Alexander, Vasko, Janos, Marits, Per, Sherif, Amir, Winqvist, Ola
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2017
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't B cells CD86 Doxorubicin Immunology Neoadjuvant chemotherapy Urinary bladder cancer B7-2 Antigen Tumor Necrosis Factor-alpha mehr... Interleukin-10 130068-27-8 80168379AG
Beschreibung
Zusammenfassung:Copyright © 2016. Published by Elsevier Inc.
Cancer is currently treated by a combination of therapies, including chemotherapy which is believed to suppress the immune system. Combination of immunotherapy and chemotherapy correlates with improved survival but needs careful planning in order to achieve a synergistic effect. In this study, we have demonstrated that doxorubicin treatment of B cells resulted in increased expression of CD86 and concordantly increased CD4+ T cell activation in the presence of superantigen, an effect that was inhibited by the addition of a CD86 blocking antibody. Furthermore, doxorubicin resulted in decreased expression of the anti-inflammatory cytokines IL-10 and TNF-α. Finally, B cells from urinary bladder cancer patients, treated with a neoadjuvant regiment containing doxorubicin, displayed increased CD86-expression. We conclude that doxorubicin induces CD86 expression on B cells and hence enhances their antigen-presenting ability in vitro, a finding verified in patients. Development of tailored time and dose schedules may increase the effectiveness of combining chemotherapy and immunotherapy
Beschreibung:Date Completed 05.06.2017
Date Revised 03.01.2021
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2016.12.003